BXOS110
/ Biocells (Beijing) Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
April 10, 2026
A Multicentre, Randomised, Double-blind, Placebo-parallel Controlled Phase Ⅲ Clinical Trial Evaluating the Efficacy and Safety of BXOS110 Injection in the Treatment of Acute Ischaemic Stroke Within 3 Hours of Onset.
(clinicaltrials.gov)
- P3 | N=1112 | Recruiting | Sponsor: Biocells (Beijing) Biotech Co.,Ltd
New P3 trial • Cardiovascular • Ischemic stroke
1 to 1
Of
1
Go to page
1